دورية أكاديمية
INTRAVITREAL RANIBIZUMAB THERAPY FOR NEOVASCULAR AGE-RELATED MACULAR DEGENERATION AND THE RISK OF STROKE: A National Sample Cohort Study
| العنوان: | INTRAVITREAL RANIBIZUMAB THERAPY FOR NEOVASCULAR AGE-RELATED MACULAR DEGENERATION AND THE RISK OF STROKE: A National Sample Cohort Study |
|---|---|
| المساهمون: | College of Medicine, Dept. of Ophthalmology, Rim, Tyler Hyungtaek, Lee, Christopher Seungkyu, Lee, Sung Chul, Kim, Do wook, Kim, Sung Soo, Kim, Do Wook, Lee, Seung Kyu, Rim, Tyler H. T. |
| بيانات النشر: | Lippincott Williams & Wilkins United States |
| سنة النشر: | 2016 |
| مصطلحات موضوعية: | Aged, 80 and over, Angiogenesis Inhibitors/therapeutic use, Choroidal Neovascularization/drug therapy, Cohort Studies, Databases, Factual, Female, Humans, Incidence, Intravitreal Injections, Male, Middle Aged, Ranibizumab/therapeutic use, Republic of Korea/epidemiology, Risk Factors, Stroke/epidemiology, Vascular Endothelial Growth Factor A/antagonists & inhibitors, Visual Acuity, Wet Macular Degeneration/drug therapy |
| الوصف: | PURPOSE: To evaluate the risk of stroke after ranibizumab treatment for neovascular age-related macular degeneration. METHODS: National registry data for 1,025,340 random subjects in the year 2002 were used. The ranibizumab group comprised patients diagnosed with neovascular age-related macular degeneration and treated with ranibizumab between 2009 and 2013 (n = 467). The two types of comparison groups were defined as comorbidity-matched controls (n = 2,330) comprised of randomly selected patients (5 per age-related macular degeneration patient), who were matched to the ranibizumab group according to sociodemographic factors, hypertension, atrial fibrillation, and the Charlson comorbidities index, and sociodemographic-matched controls (n = 2,331) matched according to sociodemographic factors only. Each sampled patient was tracked until 2013. The Cox proportional hazard regression was used. RESULTS: Stroke occurred in 6.6% of the ranibizumab group versus 7.0% of the comorbidity-matched controls and 6.7% of the sociodemographic-matched controls; these differences were not statistically significant. The overall incidence of stroke was similar for the ranibizumab group versus the comorbidity-matched controls and sociodemographic-matched controls, based on the multivariable Cox regression (hazard ratio = 0.88; 95% confidence interval, 0.60-1.30; hazard ratio = 0.95, 95% confidence interval, 0.64-1.41, respectively). CONCLUSION: Ranibizumab treatment for neovascular age-related macular degeneration did not increase the overall risk of stroke, compared with comorbidity-matched controls or sociodemographic-matched controls. ; restriction |
| نوع الوثيقة: | article in journal/newspaper |
| اللغة: | English |
| تدمد: | 0275-004X 1539-2864 |
| العلاقة: | RETINA-THE JOURNAL OF RETINAL AND VITREOUS DISEASES; J02621; OAK-2016-07802; https://ir.ymlib.yonsei.ac.kr/handle/22282913/152795Test; http://ovidsp.ovid.com/ovidweb.cgi?T=JS&CSC=Y&NEWS=N&PAGE=fulltext&AN=00006982-201611000-00017&LSLINK=80&D=ovftTest; T201605376; RETINA-THE JOURNAL OF RETINAL AND VITREOUS DISEASES, Vol.36(11) : 2166-2174, 2016 |
| DOI: | 10.1097/IAE.0000000000001084 |
| الإتاحة: | https://doi.org/10.1097/IAE.0000000000001084Test https://ir.ymlib.yonsei.ac.kr/handle/22282913/152795Test http://ovidsp.ovid.com/ovidweb.cgi?T=JS&CSC=Y&NEWS=N&PAGE=fulltext&AN=00006982-201611000-00017&LSLINK=80&D=ovftTest |
| حقوق: | CC BY-NC-ND 2.0 KR ; https://creativecommons.org/licenses/by-nc-nd/2.0/krTest/ |
| رقم الانضمام: | edsbas.3E9B3390 |
| قاعدة البيانات: | BASE |
| تدمد: | 0275004X 15392864 |
|---|---|
| DOI: | 10.1097/IAE.0000000000001084 |